168 related articles for article (PubMed ID: 32968045)
21. BRAFi induced demethylation of miR-152-5p regulates phenotype switching by targeting TXNIP in cutaneous melanoma.
Li K; Tang M; Tong S; Wang C; Sun Q; Lv M; Sun X; Wang T; Jin S
Apoptosis; 2020 Apr; 25(3-4):179-191. PubMed ID: 32056038
[TBL] [Abstract][Full Text] [Related]
22. A20 targets PFKL and glycolysis to inhibit the progression of hepatocellular carcinoma.
Feng Y; Zhang Y; Cai Y; Liu R; Lu M; Li T; Fu Y; Guo M; Huang H; Ou Y; Chen Y
Cell Death Dis; 2020 Feb; 11(2):89. PubMed ID: 32015333
[TBL] [Abstract][Full Text] [Related]
23. Quercetin Induces Mitochondrial Apoptosis and Downregulates Ganglioside GD3 Expression in Melanoma Cells.
Seo SY; Ju WS; Kim K; Kim J; Yu JO; Ryu JS; Kim JS; Lee HA; Koo DB; Choo YK
Int J Mol Sci; 2024 May; 25(10):. PubMed ID: 38791186
[TBL] [Abstract][Full Text] [Related]
24. microRNA-29a-3p, Up-Regulated in Human Gastric Cells and Tissues with H.Pylori Infection, Promotes the Migration of GES-1 Cells via A20-Mediated EMT Pathway.
Sun F; Ni Y; Zhu H; Fang J; Wang H; Xia J; Ding F; Shen H; Shao S
Cell Physiol Biochem; 2018; 51(3):1250-1263. PubMed ID: 30485838
[TBL] [Abstract][Full Text] [Related]
25. Rictor regulates the vasculogenic mimicry of melanoma via the AKT-MMP-2/9 pathway.
Liang X; Sun R; Zhao X; Zhang Y; Gu Q; Dong X; Zhang D; Sun J; Sun B
J Cell Mol Med; 2017 Dec; 21(12):3579-3591. PubMed ID: 28699701
[TBL] [Abstract][Full Text] [Related]
26. miR-550a-3-5p acts as a tumor suppressor and reverses BRAF inhibitor resistance through the direct targeting of YAP.
Choe MH; Yoon Y; Kim J; Hwang SG; Han YH; Kim JS
Cell Death Dis; 2018 May; 9(6):640. PubMed ID: 29844307
[TBL] [Abstract][Full Text] [Related]
27. FOXC1 promotes melanoma by activating MST1R/PI3K/AKT.
Wang J; Li L; Liu S; Zhao Y; Wang L; Du G
Oncotarget; 2016 Dec; 7(51):84375-84387. PubMed ID: 27533251
[TBL] [Abstract][Full Text] [Related]
28. Role of VEGFR-1 in melanoma acquired resistance to the BRAF inhibitor vemurafenib.
Atzori MG; Ceci C; Ruffini F; Trapani M; Barbaccia ML; Tentori L; D'Atri S; Lacal PM; Graziani G
J Cell Mol Med; 2020 Jan; 24(1):465-475. PubMed ID: 31758648
[TBL] [Abstract][Full Text] [Related]
29. Loss of Spry1 reduces growth of BRAF
Montico B; Colizzi F; Giurato G; Rizzo A; Salvati A; Baboci L; Benedetti D; Pivetta E; Covre A; Bo MD; Weisz A; Steffan A; Maio M; Sigalotti L; Fratta E
Cell Death Dis; 2020 May; 11(5):392. PubMed ID: 32444628
[TBL] [Abstract][Full Text] [Related]
30. Fluvastatin exerts an antitumor effect in vemurafenib-resistant melanoma cells.
Nishiya M; Yasuhira S; Shibazaki M; Oikawa H; Masuda T; Maesawa C
Anticancer Drugs; 2019 Jun; 30(5):451-457. PubMed ID: 30920401
[TBL] [Abstract][Full Text] [Related]
31. Exploiting Honokiol-induced ER stress CHOP activation inhibits the growth and metastasis of melanoma by suppressing the MITF and β-catenin pathways.
Chiu CS; Tsai CH; Hsieh MS; Tsai SC; Jan YJ; Lin WY; Lai DW; Wu SM; Hsing HY; Arbiser JL; Sheu ML
Cancer Lett; 2019 Feb; 442():113-125. PubMed ID: 30391358
[TBL] [Abstract][Full Text] [Related]
32. Berberine suppressed epithelial mesenchymal transition through cross-talk regulation of PI3K/AKT and RARα/RARβ in melanoma cells.
Kou Y; Li L; Li H; Tan Y; Li B; Wang K; Du B
Biochem Biophys Res Commun; 2016 Oct; 479(2):290-296. PubMed ID: 27639645
[TBL] [Abstract][Full Text] [Related]
33. LncRNA DBH-AS1 facilitates the tumorigenesis of melanoma by targeting miR-233-3p via IGF-1R/Akt signaling.
Chen XX; Zhang N; Fu XF; Jiang Y; Wang MY
Eur Rev Med Pharmacol Sci; 2020 Jul; 24(14):7698-7708. PubMed ID: 32744696
[TBL] [Abstract][Full Text] [Related]
34. p32 promotes melanoma progression and metastasis by targeting EMT markers, Akt/PKB pathway, and tumor microenvironment.
Sinha S; Singh SK; Jangde N; Ray R; Rai V
Cell Death Dis; 2021 Oct; 12(11):1012. PubMed ID: 34711805
[TBL] [Abstract][Full Text] [Related]
35. Casp8 acts through A20 to inhibit PD-L1 expression: The mechanism and its implication in immunotherapy.
Zou J; Xia H; Zhang C; Xu H; Tang Q; Zhu G; Li J; Bi F
Cancer Sci; 2021 Jul; 112(7):2664-2678. PubMed ID: 33934451
[TBL] [Abstract][Full Text] [Related]
36. Repurposing the serotonin agonist Tegaserod as an anticancer agent in melanoma: molecular mechanisms and clinical implications.
Liu W; Stachura P; Xu HC; Umesh Ganesh N; Cox F; Wang R; Lang KS; Gopalakrishnan J; Häussinger D; Homey B; Lang PA; Pandyra AA
J Exp Clin Cancer Res; 2020 Feb; 39(1):38. PubMed ID: 32085796
[TBL] [Abstract][Full Text] [Related]
37. Knockdown of TRIM47 inhibits breast cancer tumorigenesis and progression through the inactivation of PI3K/Akt pathway.
Wang Y; Liu C; Xie Z; Lu H
Chem Biol Interact; 2020 Feb; 317():108960. PubMed ID: 31981573
[TBL] [Abstract][Full Text] [Related]
38. Fisetin, a dietary flavonoid, augments the anti-invasive and anti-metastatic potential of sorafenib in melanoma.
Pal HC; Diamond AC; Strickland LR; Kappes JC; Katiyar SK; Elmets CA; Athar M; Afaq F
Oncotarget; 2016 Jan; 7(2):1227-41. PubMed ID: 26517521
[TBL] [Abstract][Full Text] [Related]
39. A small-molecule antagonist of CXCR1 and CXCR2 inhibits cell proliferation, migration and invasion in melanoma via PI3K/AKT pathway.
Shang FM; Li J
Med Clin (Barc); 2019 Jun; 152(11):425-430. PubMed ID: 30340844
[TBL] [Abstract][Full Text] [Related]
40. Inhibition of oncogenic BRAF activity by indole-3-carbinol disrupts microphthalmia-associated transcription factor expression and arrests melanoma cell proliferation.
Kundu A; Quirit JG; Khouri MG; Firestone GL
Mol Carcinog; 2017 Jan; 56(1):49-61. PubMed ID: 26878440
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
